Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Clinical safety and performance of VIVIA: a novel home hemodialysis system.

Bernardo AA, Marbury TC, McFarlane PA, Pauly RP, Amdahl M, Demers J, Hutchcraft AM, Leypoldt JK, Minkus M, Muller M, Stallard R, Culleton BF.

Nephrol Dial Transplant. 2017 Apr 1;32(4):685-692. doi: 10.1093/ndt/gfw044.

PMID:
27190336
2.

Prescriptions of dialysate potassium concentration during short daily or long nocturnal (high dose) hemodialysis.

Leypoldt JK, Agar BU, Bernardo AA, Culleton BF.

Hemodial Int. 2016 Apr;20(2):218-25. doi: 10.1111/hdi.12331. Epub 2015 Jul 14.

PMID:
26179136
3.

Potassium kinetics during hemodialysis.

Agar BU, Culleton BF, Fluck R, Leypoldt JK.

Hemodial Int. 2015 Jan;19(1):23-32. doi: 10.1111/hdi.12195. Epub 2014 Aug 5.

PMID:
25091596
4.

Simplified phosphorus kinetic modeling: predicting changes in predialysis serum phosphorus concentration after altering the hemodialysis prescription.

Leypoldt JK, Agar BU, Culleton BF.

Nephrol Dial Transplant. 2014 Jul;29(7):1423-9. doi: 10.1093/ndt/gfu032. Epub 2014 Feb 24.

PMID:
24569497
5.

Recovery time, quality of life, and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Rayner HC, Zepel L, Fuller DS, Morgenstern H, Karaboyas A, Culleton BF, Mapes DL, Lopes AA, Gillespie BW, Hasegawa T, Saran R, Tentori F, Hecking M, Pisoni RL, Robinson BM.

Am J Kidney Dis. 2014 Jul;64(1):86-94. doi: 10.1053/j.ajkd.2014.01.014. Epub 2014 Feb 14.

6.

Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients.

Li PK, Culleton BF, Ariza A, Do JY, Johnson DW, Sanabria M, Shockley TR, Story K, Vatazin A, Verrelli M, Yu AW, Bargman JM; IMPENDIA and EDEN Study Groups.

J Am Soc Nephrol. 2013 Nov;24(11):1889-900. doi: 10.1681/ASN.2012100987. Epub 2013 Aug 15.

7.

Determinants of phosphorus mobilization during hemodialysis.

Leypoldt JK, Agar BU, Akonur A, Hutchcraft AM, Story KO, Culleton BF.

Kidney Int. 2013 Oct;84(4):841-8. doi: 10.1038/ki.2013.205. Epub 2013 May 29.

8.

Phosphorus kinetics during hemodiafiltration: analysis using a pseudo-one-compartment model.

Leypoldt JK, Agar BU, Akonur A, Culleton BF.

Blood Purif. 2013;35 Suppl 1:59-63. doi: 10.1159/000346356. Epub 2013 Feb 25.

PMID:
23466381
9.

Physiologic volume of phosphorus during hemodialysis: predictions from a pseudo one-compartment model.

Leypoldt JK, Akonur A, Agar BU, Culleton BF.

Hemodial Int. 2012 Oct;16 Suppl 1:S15-9. doi: 10.1111/j.1542-4758.2012.00742.x.

PMID:
23036030
10.

Steady state phosphorus mass balance model during hemodialysis based on a pseudo one-compartment kinetic model.

Leypoldt JK, Agar BU, Akonur A, Gellens ME, Culleton BF.

Int J Artif Organs. 2012 Nov;35(11):969-80. doi: 10.5301/ijao.5000131.

PMID:
23065870
11.

The impact of short daily and nocturnal hemodialysis on quality of life, cardiovascular risk and survival.

Culleton BF, Asola MR.

J Nephrol. 2011 Jul-Aug;24(4):405-15. doi: 10.5301/JN.2011.8422. Review.

PMID:
21688250
12.

Assessing creatinine clearance from modification of diet in renal disease study equations in the ADEMEX cohort: limitations and potential applications.

Sloand JA, Leypoldt JK, Culleton BF, Gellens ME, Paniagua R, Amato D, Vonesh EF.

Clin J Am Soc Nephrol. 2011 Mar;6(3):598-604. doi: 10.2215/CJN.04970610. Epub 2010 Dec 16.

13.

Association between routine and standardized blood pressure measurements and left ventricular hypertrophy among patients on hemodialysis.

Khangura J, Culleton BF, Manns BJ, Zhang J, Barnieh L, Walsh M, Klarenbach SW, Tonelli M, Sarna M, Hemmelgarn BR; Alberta Kidney Disease Network.

BMC Nephrol. 2010 Jun 24;11:13. doi: 10.1186/1471-2369-11-13.

14.

Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate.

Hemmelgarn BR, Zhang J, Manns BJ, James MT, Quinn RR, Ravani P, Klarenbach SW, Culleton BF, Krause R, Thorlacius L, Jain AK, Tonelli M; Alberta Kidney Disease Network.

JAMA. 2010 Mar 24;303(12):1151-8. doi: 10.1001/jama.2010.303.

PMID:
20332400
15.

Overview of the Alberta Kidney Disease Network.

Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P, Pannu N, Ahmed SB, MacRae J, Scott-Douglas N, Jindal K, Quinn R, Culleton BF, Wiebe N, Krause R, Thorlacius L, Tonelli M.

BMC Nephrol. 2009 Oct 19;10:30. doi: 10.1186/1471-2369-10-30.

16.

Nocturnal hemodialysis does not improve overall measures of quality of life compared to conventional hemodialysis.

Manns BJ, Walsh MW, Culleton BF, Hemmelgarn B, Tonelli M, Schorr M, Klarenbach S; Alberta Kidney Disease Network.

Kidney Int. 2009 Mar;75(5):542-9. doi: 10.1038/ki.2008.639. Epub 2008 Dec 24.

17.

Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis.

James MT, Laupland KB, Tonelli M, Manns BJ, Culleton BF, Hemmelgarn BR; Alberta Kidney Disease Network.

Arch Intern Med. 2008 Nov 24;168(21):2333-9. doi: 10.1001/archinte.168.21.2333.

PMID:
19029498
18.

Access to health care among status Aboriginal people with chronic kidney disease.

Gao S, Manns BJ, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, Ahmed S, Hemmelgarn BR; Alberta Kidney Disease Network.

CMAJ. 2008 Nov 4;179(10):1007-12. doi: 10.1503/cmaj.080063.

19.

Clinical practice guidelines for assessment and management of iron deficiency.

Madore F, White CT, Foley RN, Barrett BJ, Moist LM, Klarenbach SW, Culleton BF, Tonelli M, Manns BJ; Canadian Society of Nephrology.

Kidney Int Suppl. 2008 Aug;(110):S7-S11. doi: 10.1038/ki.2008.269. No abstract available.

20.

Clinical practice guidelines for evaluation of anemia.

White CT, Barrett BJ, Madore F, Moist LM, Klarenbach SW, Foley RN, Culleton BF, Tonelli M, Manns BJ; Canadian Society of Nephrology.

Kidney Int Suppl. 2008 Aug;(110):S4-6. doi: 10.1038/ki.2008.268. No abstract available.

21.

Clinical practice guidelines for supplemental therapies and issues.

Klarenbach SW, Moist LM, Foley RN, Barrett BJ, Madore F, White CT, Culleton BF, Tonelli M, Manns BJ; Canadian Society of Nephrology.

Kidney Int Suppl. 2008 Aug;(110):S19-24. doi: 10.1038/ki.2008.271. No abstract available.

22.

Clinical practice guidelines for evidence-based use of erythropoietic-stimulating agents.

Moist LM, Foley RN, Barrett BJ, Madore F, White CT, Klarenbach SW, Culleton BF, Tonelli M, Manns BJ; Canadian Society of Nephrology.

Kidney Int Suppl. 2008 Aug;(110):S12-8. doi: 10.1038/ki.2008.270. No abstract available.

23.

Introduction to the Canadian Society of Nephrology clinical practice guidelines for the management of anemia associated with chronic kidney disease.

Manns BJ, White CT, Madore F, Moist LM, Klarenbach SW, Barrett BJ, Foley RN, Culleton BF, Tonelli M.

Kidney Int Suppl. 2008 Aug;(110):S1-3. doi: 10.1038/ki.2008.267. No abstract available.

PMID:
18668115
24.

Oral estrogen therapy in postmenopausal women is associated with loss of kidney function.

Ahmed SB, Culleton BF, Tonelli M, Klarenbach SW, Macrae JM, Zhang J, Hemmelgarn BR; Alberta Kidney Disease Network.

Kidney Int. 2008 Aug;74(3):370-6. doi: 10.1038/ki.2008.205. Epub 2008 May 21.

25.

Prevalence of chronic kidney disease and survival among aboriginal people.

Gao S, Manns BJ, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, Hemmelgarn BR; Alberta Kidney Disease Network.

J Am Soc Nephrol. 2007 Nov;18(11):2953-9. Epub 2007 Oct 17.

26.

Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial.

Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, Hemmelgarn BR, Manns BJ.

JAMA. 2007 Sep 19;298(11):1291-9.

PMID:
17878421
27.

NSAID use and progression of chronic kidney disease.

Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, Frank C, Klarenbach S, Hemmelgarn BR.

Am J Med. 2007 Mar;120(3):280.e1-7.

PMID:
17349452
28.

Derivation and validation of a clinical index for prediction of rapid progression of kidney dysfunction.

Hemmelgarn BR, Culleton BF, Ghali WA.

QJM. 2007 Feb;100(2):87-92.

PMID:
17277316
29.

Association between multidisciplinary care and survival for elderly patients with chronic kidney disease.

Hemmelgarn BR, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Walsh M, Culleton BF.

J Am Soc Nephrol. 2007 Mar;18(3):993-9. Epub 2007 Jan 31.

30.

Differences in use of peritoneal dialysis and survival among East Asian, Indo Asian, and white ESRD patients in Canada.

Hemmelgarn BR, Chou S, Wiebe N, Culleton BF, Manns BJ, Klarenbach S, Khan NA, Gourishankar S, Yeates KE, Gill JS, Tonelli M.

Am J Kidney Dis. 2006 Dec;48(6):964-71. Erratum in: Am J Kidney Dis. 2007 Feb;49(2):348.

PMID:
17162151
31.

Refined characterization of the association between kidney function and mortality in patients undergoing cardiac catheterization.

Hemmelgarn BR, Southern DA, Humphries KH, Culleton BF, Knudtson ML, Ghali WA; Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Investigators.

Eur Heart J. 2006 May;27(10):1191-7. Epub 2006 Mar 30.

PMID:
16574688
32.

Progression of kidney dysfunction in the community-dwelling elderly.

Hemmelgarn BR, Zhang J, Manns BJ, Tonelli M, Larsen E, Ghali WA, Southern DA, McLaughlin K, Mortis G, Culleton BF.

Kidney Int. 2006 Jun;69(12):2155-61. Epub 2006 Mar 8.

34.

Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology.

Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, Culleton BF; Canadian Society of Nephrology Committee for Clinical Practice Guidelines.

J Am Soc Nephrol. 2006 Mar;17(3 Suppl 1):S1-27. Review. No abstract available.

35.

Contrast-induced nephropathy: epidemiology and prevention.

Bagshaw SM, Culleton BF.

Minerva Cardioangiol. 2006 Feb;54(1):109-29. Review.

PMID:
16467746
36.
37.

Impact of anemia on hospitalization and mortality in older adults.

Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR.

Blood. 2006 May 15;107(10):3841-6. Epub 2006 Jan 10.

38.
39.

Survival after coronary revascularization among patients with kidney disease.

Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA; Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Investigators.

Circulation. 2004 Oct 5;110(14):1890-5. Epub 2004 Sep 27. Review.

PMID:
15451786
40.

Acetylcysteine and renal function following coronary angiographic procedures.

Bagshaw SM, Culleton BF.

JAMA. 2003 Jun 4;289(21):2795; author reply 2796. No abstract available.

PMID:
12783908
41.

Is chronic kidney disease a cardiovascular disease risk factor?

Culleton BF, Hemmelgarn BR.

Semin Dial. 2003 Mar-Apr;16(2):95-100. Review.

PMID:
12641871
42.

Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines.

Culleton BF, Wilson PW.

J Am Soc Nephrol. 1998 Dec;9(12 Suppl):S5-15. Review.

PMID:
11443768
43.

Uric acid and cardiovascular disease: a renal-cardiac relationship?

Culleton BF.

Curr Opin Nephrol Hypertens. 2001 May;10(3):371-5. Review.

PMID:
11342800
44.

Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study.

Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D.

Am J Med. 2000 Jul;109(1):1-8.

PMID:
10936471
45.

Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency.

Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D.

Kidney Int. 1999 Dec;56(6):2214-9.

46.

Prevalence and correlates of elevated serum creatinine levels: the Framingham Heart Study.

Culleton BF, Larson MG, Evans JC, Wilson PW, Barrett BJ, Parfrey PS, Levy D.

Arch Intern Med. 1999 Aug 9-23;159(15):1785-90.

PMID:
10448783
47.

Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study.

Culleton BF, Larson MG, Kannel WB, Levy D.

Ann Intern Med. 1999 Jul 6;131(1):7-13.

PMID:
10391820
48.

Hyperhomocysteinemia in chronic renal disease.

Bostom AG, Culleton BF.

J Am Soc Nephrol. 1999 Apr;10(4):891-900. Review. No abstract available.

49.

Epidemiology of cardiovascular disease in the United States.

Wilson PW, Culleton BF.

Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S56-65. Review.

PMID:
9820465
50.

Cardiac disease in diabetic end-stage renal disease.

Foley RN, Culleton BF, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE.

Diabetologia. 1997 Nov;40(11):1307-12.

PMID:
9389423

Supplemental Content

Loading ...
Support Center